Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

被引：0
|
作者：
Dhanashree Ratra
Krishnakanta Roy
Sneha Giridhar
Sushant Madaan
机构：
[1] Medical Research Foundation,Department of Vitreoretinal Diseases
[2] Sankara Nethralaya,undefined
来源：
Ophthalmology and Therapy | 2022年 / 11卷
关键词：
Anti VEGF; Biosimilar; Comparison with bevacizumab; DME; nAMD; Ranibizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：135 / 149
页数：14
相关论文
共 50 条
  • [1] Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
    Ratra, Dhanashree
    Roy, Krishnakanta
    Giridhar, Sneha
    Madaan, Sushant
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (01) : 135 - 149
  • [2] Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
    Soman, Manoj
    Nair, Indu
    Sheth, Jay U.
    Nair, Unnikrishnan
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (03) : 1175 - 1186
  • [3] Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
    Manoj Soman
    Indu Nair
    Jay U. Sheth
    Unnikrishnan Nair
    Ophthalmology and Therapy, 2022, 11 : 1175 - 1186
  • [4] Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data
    Ashish Sharma
    M. Hafeez Faridi
    Nilesh Kumar
    Nikulaa Parachuri
    Rohini Sharma
    Baruch D. Kuppermann
    Francesco Bandello
    Anat Loewenstein
    Carl D. Regillo
    Eye, 2020, 34 : 1008 - 1009
  • [5] Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data
    Sharma, Ashish
    Hafeez Faridi, M.
    Kumar, Nilesh
    Parachuri, Nikulaa
    Sharma, Rohini
    Kuppermann, Baruch D.
    Bandello, Francesco
    Loewenstein, Anat
    Regillo, Carl D.
    EYE, 2020, 34 (06) : 1008 - 1009
  • [6] Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers
    Vaidyanathan, Arvind
    Vana, Pranaya
    Joshi, Nachiket
    Sourav, Bikash
    Bhargava, Prabhat
    John, George
    Ramaswamy, Anant
    Ostwal, Vikas
    SOUTH ASIAN JOURNAL OF CANCER, 2024, 13 (04) : 296 - 299
  • [7] Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial) : Real-World Evidence
    Chakraborty, Debdulal
    Mondal, Soumen
    Boral, Subhendu
    Das, Arnab
    Sinha, Tushar Kanti
    Majumdar, Saptorshi
    Bhattacharya, Ranabir
    Maitra, Ritobroto
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 1067 - 1076
  • [8] Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity
    Maitra, Puja
    Jaju, Sujay
    Agrawal, Kushal U.
    Das, Abhishek
    Subramaniam, Prema
    Venkatapathy, Narendran
    Shah, Parag K.
    EYE, 2025,
  • [9] Biosimilar Ranibizumab and Innovator Ranibizumab-Immunogenicity Assessment and Its Impact on Safety and Efficacy
    Sharma, Ashish
    Kumar, Nilesh
    Kuppermann, Baruch D.
    JAMA OPHTHALMOLOGY, 2023, 141 (02) : 128 - 129
  • [10] Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema
    Koc, Irem
    Kadayifcilar, Sibel
    Eldem, Bora
    OPHTHALMOLOGICA, 2018, 239 (2-3) : 85 - 93
12345